The purpose of the present invention is to provide a sepetaprost-containing eye drop having exceptional formulation stability. The present invention relates to an eye drop containing sepetaprost, the eye drop being accommodated in an ethylene-oxide-gas-sterilized eye drop container.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
C07D 313/06 - Cycles à sept chaînons condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
Provided are an inspection system, an inspection method, and a program, all of which are for improving detection accuracy of a foreign object in a container filled with a liquid. The inspection system comprises a rotation control unit that performs control for rotating the container around a horizontal axis in a direction in which the inclination of the central axis with respect to the vertical axis increases while rotating the container around the central axis of the container filled with the liquid.
The present disclosure provides the methods for making 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid. The present disclosure also generally relates to intermediates useful in the said methods.
C07D 311/96 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, condensés avec d'autres cycles condensés en spiro avec des carbocycles ou avec des systèmes carbocycliques
The present invention addresses the problem of providing: an antibody that recognizes an HLA-A24/HF10 peptide complex on a cancer cell surface; a pharmaceutical composition comprising the antibody, in particular, a pharmaceutical composition for treating cancer and a use thereof; and a method for treating cancer. Provided is a multispecific antibody having an antigen-binding site that recognizes a complex of a polypeptide represented by SEQ ID NO: 3 and an MHC molecule.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
(wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
C07C 233/81 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle
C07C 235/64 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés en position ortho à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 327/48 - Amides d'acides thiocarboxyliques ayant des atomes de carbone de groupes thiocarboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations; medicines for veterinary purposes;
medicated toiletry preparations; sanitary preparations for
medical purposes; fungicides; sterilizing preparations;
disinfectants for hygiene purposes; pharmaceutical
preparations for the treatment and prevention of
cardiovascular disorders, genitourinary disorders,
gynecological diseases and obstetric diseases, cancer and
its metastasis, eye disorders, neurologic disorders,
psychiatric disorders, endocrine and metabolic disorders,
allergic disorders, gastrointestinal disorders, immune
diseases and autoimmune diseases, respiratory diseases,
musculoskeletal and connective tissue disorders, infectious
diseases, dermatologic disorders, hematological disorder,
inflammatory diseases, ear, nose, dental and throat
disorders, hepatic and biliary disorders, alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; candy, medicated;
pastilles for pharmaceutical purposes; mint for
pharmaceutical purposes; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilized food
adapted for medical purposes; lyophilized meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Beauty salon services; barber shop services; providing bath
houses; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo-seifuku]; bodywork therapy;
acupuncture; provision of medical and pharmaceutical
information via the Internet; provision of medical
information relating to benefits, side effects, interactions
of pharmaceuticals and medications; provision of medical
information about pharmaceutical products; medical,
medicinal and pharmaceutical consultancy; advisory services
relating to pharmaceutical products; provision of
information on pharmaceuticals and medical services through
computer databases; medical testing for the collection of
medical information, analysis and provision of medical
information for diagnostic or treatment purposes; medical
testing; medical consultancy and diagnosis via the Internet;
online medical counseling services; remote monitoring of
medical data for medical diagnosis and treatment; analysis
and provision of clinical data of patients for diagnostic or
treatment purpose; provision of medical information;
physical examination; providing information about
pharmaceuticals, medical services or health; consultancy
services relating to medical services, pharmaceuticals,
health or dispensing of medications; consultancy, advisory
and provision of information relating to dieting,
nutritional intake or health care; consultancy, advisory and
provision of information relating to health care; managed
health care services; provision of records of personal
health information data such as weight, body fat, body
temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
Disclosed is a compound of formula (I), wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis
14.
HUMAN-DERIVED ANTI-COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 (CRMP2) ANTIBODIES
Collapsin Response Mediator Protein 2 (CRMP2) is established as a therapeutic target in neurodegenerative disorders. Provided are novel human-derived anti-CRMP2 antibodies as well as fragments, derivatives and variants thereof. Polynucleotides, vectors, host cells and kits related to the CRMP2 specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical compositions for CRMP2 targeted therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A compound represented by the general formula (V)
A compound represented by the general formula (V)
A compound represented by the general formula (V)
wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
C07D 205/04 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07C 49/252 - Composés non saturés comportant des groupes cétone liés à des atomes de carbone acycliques contenant des groupes hydroxyle contenant des cycles aromatiques à six chaînons et d'autres cycles
C07C 49/577 - Composés non saturés comportant des groupes cétone liés à des cycles autres que des cycles aromatiques à six chaînons contenant des groupes éther, des groupes , des groupes ou des groupes
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical substances; anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes; diagnostic preparations; medicines for veterinary purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; anesthetic, sedative and analgesic drugs; vaccines; reagent paper for medical purposes; vitamin preparations; candy, medicated; pastilles for pharmaceutical purposes; mint for pharmaceutical purposes; chewing gum for medical purposes; lecithin for medical purposes; greases for medical purposes; cod liver oil; capsules for medicines; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; glucose dietary supplements; lecithin dietary supplements; nutritional supplements; dietary supplements mainly consisting of seafood extracts in the form of powders, pills, capsules, granules, jellies or liquids; dietary supplements for humans; dietary fibre; lyophilized food adapted for medical purposes; lyophilized meat adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; nutritional supplements for animals; dietary supplements for animals; semen for artificial insemination. Beauty salon services; barber shop services; providing bath houses; massage and therapeutic shiatsu massage; chiropractic; moxibustion; treatment for dislocated joints, sprain, bone fractures [judo-seifuku]; bodywork therapy; acupuncture; provision of medical and pharmaceutical information via the Internet; provision of medical information relating to benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for diagnostic or treatment purpose; provision of medical information; physical examination; providing information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to dieting, nutritional intake or health care; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nutritional consultancy and advisory for preventing and decreasing obesity; provision of information about nutritional consultancy and advisory for preventing and decreasing obesity; dietary and nutritional guidance; animal breeding; veterinary services; beautification for animals; nursing care; rental of medical apparatus and instruments.
The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
The problem addressed by the present invention is to provide a novel preparation that contains an anti-PD-1/CD3 bispecific antibody as an active ingredient and that is for the prevention, suppression of symptom development, suppression of recurrence, or treatment of autoimmune diseases, or a graft-versus-host disease (GVHD) or hematological cancer. The invention provides an aqueous pharmaceutical composition and a preparation comprising same. The aqueous pharmaceutical composition contains an anti-PD-1/CD3 bispecific antibody as an active ingredient, and further contains, for example, an acetate buffer, trehalose, L-methionine, polysorbate 80, and sodium chloride. The aqueous pharmaceutical composition can be used for both subcutaneous and intravenous administration in the form of single excipient composition.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 21/04 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire de la myasthénie
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
To provide a compound having EP3 agonist activity. A compound represented by general formula (I) (in the formula, all symbols are as defined in the description) or a salt thereof has strong EP3 agonist activity and can therefore be used as an EP3 agonist.
C07D 313/06 - Cycles à sept chaînons condensés avec des carbocycles ou avec des systèmes carbocycliques
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 407/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Provided is a prophylactic and/or therapeutic agent for kidney diseases. The present invention provides a prophylactic and/or therapeutic agent for kidney diseases (for example, chronic kidney disease, acute kidney failure, or the like) that contains a compound represented by general formula (I) (wherein all the symbols are as defined in the description) or a salt thereof.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is provided, which is useful as a pharmaceutical ingredient having GBA1 and GCS dual modulatory activity in the prevention and/or treatment of a disease associated with GBA1 and/or GCS, in which all symbols represent the same meaning as the symbols described in the specification. A drug is also provided, which containing, as an active ingredient, a compound having GBA1 and GCS dual modulatory activity in prevention and/or treatment of a disease associated with GBA1 and/or GCS.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
An effective cancer treatment method is disclosed. According to the cancer treatment method, a CD47 inhibitory substance, an immune checkpoint inhibitory substance (for example, an anti-PD-1 antibody), and a standard therapy (for example, a combination therapy in which Bevacizumab or Cetuximab is added to FOLFOX therapy for radically unresectable advanced or recurrent colorectal cancer, or FOLFIRINOX therapy or a dose-reduced regimen thereof for pancreatic cancer having distant metastasis) are combined. The treatment method is useful for cancer treatment.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 35/60 - Poissons, p. ex. hippocampesŒufs de poisson
A23L 17/30 - Œufs de poisson, p. ex. caviarSuccédanés d'œufs de poisson
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
26.
THERAPEUTIC AGENT FOR SOLID CANCERS, WHICH COMPRISES AXL INHIBITOR AS ACTIVE INGREDIENT
KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (Japon)
Inventeur(s)
Takayama, Koichi
Yamada, Tadaaki
Yasuhiro, Tomoko
Tanaka, Kohei
Abrégé
A therapeutic agent for solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and to be administered in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination has strong antitumor effect and is therefore useful for treatment of solid cancers.
Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
28.
MODULATORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION
Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
An antibody or antigen-binding fragment thereof is disclosed. The antibody or antigen-binding fragment thereof binds to HER2 expressed on a cancer cell or a fragment of the HER2. A HER2-targeting agent containing any of the antibody or antigen-binding fragment thereof, and a pharmaceutical composition containing the HER2-targeting agent are disclosed.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
30.
INFORMATION PROCESSING DEVICE, PROGRAM, AND INFORMATION PROCESSING METHOD
[Problem] To provide an information processing device that is capable of reducing the burden on a user and contributing to improvement in the mental state of the user. [Solution] According to one aspect of the present invention, an information processing device is provided. This information processing device comprises a receiving unit, an extracting unit, and an output unit. The receiving unit receives first mood information pertaining to the mood of a first user. On the basis of the first mood information and reference information, the extracting unit extracts experience diary information which pertains to an experience diary kept by a second user who is different from the first user. The reference information is information indicating the relationship between second mood information about the mood of the second user and the experience diary information. The output unit outputs the experience diary information.
G16H 20/70 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mentales, p. ex. la thérapie psychologique ou le training autogène
G16Y 20/40 - Information détectée ou collectée par les objets relative aux données personnelles, p. ex. données biométriques, enregistrement ou préférences
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represented by general formula (I) (in the formula, all symbols have the same meanings as the symbols described in the description) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity, and is therefore useful as a drug component having potent ABHD6 inhibitory activity in the prevention and/or treatment of diseases associated with ABHD6.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention addresses the problem of providing a compound having inhibitory activity against DGK α and/or ζ. As a result of diligent study, the inventors of the present invention found, as a substance that can solve the above problem, a compound which has inhibitory activity against DGK α and/or ζ and which is represented by general formula (IY) [where all symbols in the formula have the same meaning as set forth in the specification]. A compound according to the present invention, which is represented by general formula (IY), has inhibitory activity against DGK α and/or ζ, and thus can be used as an active ingredient in an agent for inhibiting the progression of, inhibiting the recurrence of, and/or for treating cancer or infectious diseases, for example.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
The present invention addresses the problem of providing a novel drug for preventing cancer, suppressing the progression of a symptom of cancer, suppressing the recurrence of cancer, or treating cancer. As the results of intensive studies, the present inventors focused attention on Allergin-1 that is a target molecule involved in the regulation of cancer immunity, and found a bispecific antibody capable of binding specifically respectively to two different epitopes on the S1 and S2 domains, said domains being the extracellular domains of Allergin-1, as a substance that can solve this problem. The present inventors confirmed that this antibody is useful for preventing cancer, suppressing the progression of a symptom of cancer, suppressing the recurrence of cancer, or treating cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:
in which all symbols represent the same meaning as the symbols described in the specification.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
An antibody that binds to HER2 expressed on a cancer cell or a fragment of the HER2, or an antigen binding fragment thereof are disclosed. Uses of the antibody or antigen binding fragment thereof are disclosed. The antibody or antigen binding fragment thereof is useful to target a HER2 expressing cancer cells. A-pharmaceutical composition containing the antibody or antigen binding fragment thereof is also disclosed.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
The problem addressed by the present invention is to provide a method for determining haplotype based on a combination of multiple single nucleotide polymorphisms (SNP) in the human STING1 gene. As a result of in-depth studies by the present inventors, such a method was established, and the present invention was completed. Specifically, the present invention provides a method for determining haplotype based on the combination of four SNP each identified by rs7380824, rs1131769, rs78233829, and rs11554776 in the human STING1 gene.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
39.
NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
Eisai R&D Management Co., Ltd. (Japon)
Ono Pharmaceutical Co., Ltd. (Japon)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japon)
Inventeur(s)
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Yamamoto, Takeshi
Wakabayashi, Takeshi
Abrégé
An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.
An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/353 - 3,4-Dihydrobenzopyranes, p. ex. chromane, catéchine
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1):
wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/06 - Composés du phosphore sans liaisons P—C
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
42.
COMPOSITION FOR OPHTHALMIC USE CONTAINING SEPETAPROST
The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of shelf life of this composition for ophthalmic use. The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w/v) and has a pH within a range from 5 to 8.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof. Examples of LPA3 agonists include compounds having a structural formulae (IA) to (IIIA) are disclosed as agonists or antagonist of EDG7 (=LPA3) receptor:
A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof. Examples of LPA3 agonists include compounds having a structural formulae (IA) to (IIIA) are disclosed as agonists or antagonist of EDG7 (=LPA3) receptor:
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
16 - Papier, carton et produits en ces matières
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
32 - Bières; boissons non alcoolisées
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemicals for use in the manufacture of pharmaceuticals;
chemicals for use in the manufacture of cosmetics; chemicals
for use as food additives; chemicals; glue and adhesives for
industrial purposes; plant growth regulating preparations;
fertilizers; ceramic glazings; priming putty; higher fatty
acids; silicon; rare earths; mercury; radium for scientific
purposes; non-metallic minerals; chemical compositions for
developing and printing photographs; reagent paper [not for
medical purposes]; artificial sweeteners; flour and starch
for industrial purposes; synthetic resins, unprocessed;
plastics [raw materials]; groundwood pulp or chemical pulps
for manufacturing purposes. Antistatic preparations for household purposes; de-greasing
preparations for household purposes; rust removing
preparations; stain removing benzine; fabric softeners for
laundry use; laundry bleach; adhesives for affixing false
hair; laundry starch; seaweed gelatine for laundry use
[funori]; adhesives for affixing false eyelashes; breath
freshening preparations; deodorants for animals; paint
stripping preparations; shoe cream; shoe black [shoe
polish]; polishing preparations; soaps and detergents;
dentifrices; cosmetics; perfumery; fragrances; food
flavourings [essential oils]; incense; abrasive paper
[sandpaper]; abrasive cloth; abrasive sand; artificial
pumice stone; polishing paper; false nails; false eyelashes. Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc. Finger guards for medical purposes; pacifiers for babies;
ice bag pillows for medical purposes; triangular bandages;
support bandages; surgical catguts; feeding cups for medical
purposes; dropping pipettes for medical purposes; teats;
medical ice bags; medical ice bag holders; baby bottles;
nursing bottles; contraceptives, non-chemical; artificial
tympanic membranes; prosthetics or fillings materials, not
for dental use; ear plugs for sleeping; ear plugs for
soundproofing; esthetic massage apparatus for commercial
use; medical apparatus and instruments; electric massage
apparatus for household purposes; gloves for medical
purposes; urinals for medical purposes; bed pans; ear picks;
sanitary masks. Pastes and other adhesives for stationery or household
purposes; sealing wax; printers' reglets; printing type;
addressing machines; ink ribbons; automatic stamp affixing
machines; electric staplers for offices; envelope sealing
machines for offices; stamp obliterating machines; drawing
instruments; typewriters; checkwriters; mimeographs; relief
duplicators; paper shredders for office use; franking
machines; rotary duplicators; marking templates; decorators'
paintbrushes; paperboard packaging containers for
pharmaceuticals; containers of paper, for packaging; bags
[pouches] of plastics, for packaging; food wrapping plastic
film for household purposes; garbage bags of paper for
household purposes; garbage bags of plastics for household
purposes; paper patterns; tailors' chalk; banners of paper;
flags of paper; hygienic hand towels of paper; towels of
paper; table napkins of paper; hand towels of paper;
handkerchiefs of paper; shipping tags; printed paper for
lot, other than toy; wrapping paper for medicine dispensing
machine; paper and cardboard; stationery; pamphlets relating
to medicine and pharmaceuticals; magazines relating to
medical services and pharmaceuticals; catalogues relating to
pharmaceuticals and medical services; printed matter;
paintings and calligraphic works; photographs; photograph
stands. Fruit-based, vegetable-based, bean-based or nut-based
snacks; edible oils and fats; milk products; meat; eggs;
fresh, chilled or frozen edible aquatic animals [not live];
frozen vegetables; frozen fruits; processed meat products;
processed seafood products; processed vegetables and fruits;
fried tofu pieces [abura-age]; freeze-dried tofu pieces
[kohri-dofu]; jelly made from devils' tongue root
[konnyaku]; soya milk; tofu; fermented soybeans [natto];
processed eggs; pre-cooked curry stew, stew and soup mixes;
dried flakes of laver for sprinkling on rice in hot water
[ochazuke-nori]; furi-kake [dried flakes of fish, meat,
vegetables or seaweed]; side-dish made of fermented soybean
[name-mono]; preserved pulses. Aromatic preparations for food, not from essential oils;
tea; coffee; cocoa; ice; sweets; confectionery; candies;
pastries; cakes; fondants [confectionery]; bread and buns;
sandwiches; steamed buns stuffed with minced meat
[chuka-manjuh]; hamburgers [sandwiches]; pizzas; hot dog
sandwiches; meat pies; seasonings; condiments; spices; ice
cream mixes; sherbet mixes; unroasted coffee beans; cereal
preparations; chocolate spread; Chinese stuffed dumplings
[gyoza, cooked]; Chinese steamed dumplings [shumai, cooked];
sushi; fried balls of batter mix with small pieces of
octopus [takoyaki]; boxed lunches consisting of rice, with
added meat, fish or vegetables; ravioli; yeast powder; koji
[fermented malted rice]; yeast; baking powder; instant
confectionery mixes; pasta sauce; by-product of rice for
food [sake lees]; gluten for food; flour. Beer; carbonated drinks [refreshing beverages]; soft drinks;
fruit juices; vegetable juices [beverages]; extracts of hops
for making beer; whey beverages. Retail services or wholesale services for foods and
beverages; retail services or wholesale services for dietary
supplements for humans; retail services or wholesale
services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; retail services or
wholesale services for cosmetics, toiletries, dentifrices,
soaps and detergents; retail services or wholesale services
for printed matter; retail services or wholesale services
for paper and stationery; retail services or wholesale
services for measures; retail services or wholesale services
for medical apparatus and instruments; arranging, conducting
and organization of exhibitions for sales promotion of
pharmaceuticals, medical apparatus and instruments;
arranging, conducting and organization of trade fairs for
sales promotion of pharmaceuticals, medical apparatus and
instruments; advertising services relating to pharmaceutical
products; advertising and publicity services; marketing
research in the field of medical services or
pharmaceuticals; business consulting and advisory services
relating to improvement of pharmaceutical productivity;
business consulting and advisory services in the field of
pharmaceuticals; marketing research relating to
pharmaceuticals; compilation and provision of business
statistical information relating to the pharmaceutical
industry; providing information concerning commercial sales
of pharmaceuticals, cosmetics and foods; providing
information concerning commercial sales of health foods,
dietary supplements and healthcare products; business
planning and organization for healthcare business; business
management analysis or business consultancy; business
management; marketing research or analysis; providing
information concerning commercial sales; administrative
services for the referral of medical doctors, dentists,
nurses and pharmacists; employment agency services;
import-export agencies; office functions, namely filing, in
particular documents or magnetic tapes; compilation of
pharmaceutical research information into computer database;
compilation of information into computer databases;
systemization, updating and maintenance of clinical data
relating to clinical trials of pharmaceutical products at
medical institutions and clinical data of patients in
computer database; maintaining records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; updating and maintenance of data in computer
databases; compilation and systemization of information into
computer databases; providing business assistance to others
in the operation of data processing apparatus namely,
computers, typewriters, telex machines and other similar
office machines; reception services for visitors in
buildings [office functions]; publicity material rental;
providing commercial information and advice for consumers in
the choice of products and services; providing employment
information; computational data processing. Acceptance of deposits [including substitute bond issuance]
and acceptance of fixed interval installment deposits; loans
[financing] and discount of bills; domestic exchange
settlement; liability guarantee and acceptance of bills;
securities lending; acquisition and transfer of monetary
claims; safekeeping of valuables including securities and
precious metals [safe deposit services]; exchanging money;
trusteeship of financial futures contracts; trusteeship of
money, securities, monetary claims, personal property, land,
rights on land fixtures, surface rights or lease on land;
agencies for bond subscriptions; foreign exchange
transactions; letter-of-credit related services; brokerage
of credit purchase; venture capital funding; venture capital
fund management; venture capital funding services to
emerging and start-up companies; issuance of tokens of
value; agencies for collecting gas or electric power utility
payments; consigned collection of payment for goods; buying
and selling of securities; trading of securities index
futures; trading of securities options; trading of overseas
market securities futures; agencies for brokerage of
securities, securities index futures, securities options,
and overseas market securities futures; agencies for
brokerage of securities, securities index futures and
securities options in domestic markets; agencies for
brokerage of securities and securities index futures in
overseas markets; agencies for brokerage of forward
agreement of securities, for forward agreement of securities
index futures, for forward agreement of securities options,
spot and forward transaction of securities index futures;
brokerage for securities liquidation; securities
underwriting; securities offering; brokerage services
relating to securities subscription or offering; providing
stock market information; agencies for commodity futures
trading; life insurance brokerage; life insurance
underwriting; agencies for non-life insurance; claim
adjustment for non-life insurance; non-life insurance
underwriting; insurance premium rate computing; management
of buildings; agency services for the leasing or rental of
buildings; leasing or renting of buildings; purchase and
sale of buildings; real estate agency services for the
purchase or sales of buildings; real estate appraisal;
providing information on buildings or land [real estate
affairs]; land management; agency services for the leasing
or rental of land; leasing of land; purchase and sale of
land; real estate agency services for the purchase or sales
of land; providing monetary grants for medical project;
providing monetary grants for research and development of
pharmaceuticals and medical technology; providing monetary
grants for medical research and medical education; providing
project grants for social welfare, healthcare, medical,
education, sport, physical exercise and environmental
conservation programmes; advisory services relating to
financial grants; provision of information relating to
provision of grants; provision of grants; arranging and
organization of charitable fundraising for volunteer and
welfare activities; arranging and organization of
fundraising for charitable activities; providing information
relating to charitable fund raising; charitable fund-raising
services to support medical research; charitable fund
raising; fund raising services. Educational and training services relating to medicine and
pharmaceuticals, and providing information relating thereto;
educational and training services relating to clinical
trials of pharmaceutical products; providing educational and
training services relating to medical services and
pharmaceuticals via cable communication and computer network
communication; educational and instruction services relating
to preventing and decreasing obesity; educational and
training services relating to nutrition, health, health
care, fitness, medical services and pharmaceuticals;
educational and instruction services relating to medical
services; educational and instruction services relating to
environmental issues; educational and instruction services
relating to arts, crafts, sports or general knowledge;
providing information on donation of human corpses for
medical education; arranging of donation of human corpses
for medical education; arranging, conducting and
organization of seminars, symposiums or conferences relating
to medical services, pharmaceuticals, health and health
care; arranging and conducting of workshops or training
relating to health, medical service and pharmaceuticals;
arranging, conducting and organization of seminars,
workshops or training relating to preventing and decreasing
obesity; arranging, conducting and organization of seminars,
workshops or training relating to nutrition, health, health
care, fitness, medical services and pharmaceuticals;
arranging, conducting and organization of seminars,
workshops or training relating to environmental issues;
arranging, conducting and organization of seminars or events
relating to environmental conservation; arranging,
conducting and organization of seminars; providing online
electronic publications relating to medical technologies,
biotechniques or pharmaceuticals; providing electronic
dictionaries and encyclopedias via the internet; providing
electronic publications; services of reference libraries for
literature and documentary records; book rental; online
provision of images, movies, videos, music or texts;
publication of books; providing videos from the internet,
not downloadable; providing digital music from the internet,
not downloadable; production of radio or television programs
relating to medical services, pharmaceuticals, health and
health care; production of radio or television programs;
production of videos relating to medical services,
pharmaceuticals, health and health care [not for movies or
television programs and not for advertising or publicity];
production of videos in the field of education, culture,
entertainment or sports [not for movies or television
programs and not for advertising or publicity];
organization, arranging and conducting of sports
competitions; arranging, conducting and organization of
events for preventing and decreasing obesity; arranging,
conducting and organization of events relating to nutrition,
health, health care, fitness, medical services and
pharmaceuticals for educational purposes; organization of
entertainment events excluding movies, shows, plays, musical
performances, sports, horse races, bicycle races, boat races
and auto races; providing sports facilities; providing
amusement facilities; providing facilities for movies,
shows, plays, music or educational training; rental of
sports equipment; toy rental; translation. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; providing information relating to
testing or research on pharmaceuticals via the internet;
research and development of pharmaceuticals and
biopharmaceuticals for treatment and diagnosis of human
disease; research and testing of pharmaceuticals for gene
analysis; providing information relating to research and
development of pharmaceuticals in response to customers'
request via the internet; providing information about
medical and scientific research in the field of
pharmaceuticals; clinical trials for pharmaceuticals;
conducting clinical trials for pharmaceutical products at
medical institutions; providing information about the
results of clinical trials for pharmaceuticals; testing,
inspection or research on pharmaceuticals, chemicals,
cosmetics or foods and providing information relating
thereto; providing research information and results in the
fields of technology, science and medicine from an online
searchable database; providing information about
environmental conservation; environmental testing and
inspection services; providing information about
environmental testing or research relating to environmental
conservation; research on building construction or city
planning; testing or research on prevention of pollution;
testing or research on electricity; testing or research on
civil engineering; testing, inspection or research on
agriculture, livestock breeding or fisheries; testing or
research on machines, apparatus and instruments; rental of
measuring apparatus; rental of computers; providing computer
programs on data networks; software as a service [SaaS];
electronic storage of records of personal health information
data of individuals such as weight, body fat, body
temperature, number of steps, sleeping hours and blood
pressure; rental of laboratory apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical consultancy and diagnosis via the internet; online
medical counseling services; remote monitoring of patient
health status for medical conditions; analysis and provision
of clinical data of patients for diagnostic or treatment
purpose; providing medical information; physical
examination; providing information about pharmaceuticals,
medical services or health; consultancy services relating to
medical services, pharmaceuticals, health or dispensing of
medications; consultancy, advisory and provision of
information relating to dieting, nutritional intake or
health care; consultancy, advisory and provision of
information relating to health care; managed health care
services; provision of records of personal health
information data such as weight, body fat, body temperature,
number of steps, sleeping hours and blood pressure;
nutritional consultancy and advisory for preventing and
decreasing obesity; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of medical apparatus and instruments.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc; audio and video recordings. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; pharmaceutical research; providing
information relating to pharmaceutical research; providing
information relating to testing or research on
pharmaceuticals via the Internet; research and development
of pharmaceuticals and biopharmaceuticals for treatment and
diagnosis of human disease; research and survey of
pharmaceuticals for gene analysis; providing information
relating to research and development of pharmaceuticals in
response to customers' request via the Internet; providing
information about medical and scientific research in the
field of pharmaceuticals; clinical trials; clinical trials
for pharmaceuticals; conducting clinical trials for
pharmaceutical products at medical institutions; providing
information about the results of clinical trials for
pharmaceuticals; testing, inspection or research on
pharmaceuticals, chemicals, cosmetics or foods and providing
information relating thereto; providing research information
and results in the fields of technology, science and
medicine from an online searchable database; providing
information about environmental conservation; testing and
inspection services relating to environmental conservation;
providing information about testing or research relating to
environmental conservation; research on building
construction or city planning; testing or research on
prevention of pollution; testing or research on electricity;
testing or research on civil engineering; testing,
inspection or research on agriculture, livestock breeding or
fisheries; testing or research on machines, apparatus and
instruments; rental of measuring apparatus; rental of
computers; providing computer programs on data networks;
software as a service [SaaS]; electronic storage of medical
records; electronic storage of records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; electronic data storage; rental of laboratory
apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic Shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the Internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical testing; medical consultancy and diagnosis via the
Internet; online medical counseling services; remote
monitoring of patient health status for medical conditions;
remote monitoring of medical data for medical diagnosis and
treatment; analysis and provision of clinical data of
patients for diagnostic or treatment purpose; providing
medical information; physical examination; providing
information about pharmaceuticals, medical services or
health; consultancy services relating to medical services,
pharmaceuticals, health or dispensing of medications;
consultancy, advisory and provision of information relating
to dieting, nutritional intake or health care; consultancy,
advisory and provision of information relating to health
care; managed health care services; provision of records of
personal health information data such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorder, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilised food
adapted for medical purposes; lyophilised meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Laboratory apparatus and instruments; photographic machines
and apparatus; cinematographic machines and apparatus;
optical machines and apparatus; measures; measuring or
testing machines and instruments; telecommunication machines
and apparatus; personal digital assistants; application
software; computer programs; computers; computer programs
and software; computer hardware; computer systems; computer
terminals; computer peripheral devices; dust masks; gas
masks; welding masks; game programs for home video game
machines; downloadable music files; downloadable image
files; downloadable video files; downloadable digital books;
downloadable electronic newspapers; electronic publications;
books recorded on disc; audio and video recordings. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer software design,
computer programming, or maintenance of computer software
relating to medical data; design and development of computer
software for use with medical technology; development and
creation of computer programmes for data processing; rental
of computers and software for data processing; computer
software design, computer programming, or maintenance of
computer software; database design and development;
technological advice relating to computers, automobiles and
industrial machines; pharmaceutical research; providing
information relating to pharmaceutical research; providing
information relating to testing or research on
pharmaceuticals via the Internet; research and development
of pharmaceuticals and biopharmaceuticals for treatment and
diagnosis of human disease; research and survey of
pharmaceuticals for gene analysis; providing information
relating to research and development of pharmaceuticals in
response to customers' request via the Internet; providing
information about medical and scientific research in the
field of pharmaceuticals; clinical trials; clinical trials
for pharmaceuticals; conducting clinical trials for
pharmaceutical products at medical institutions; providing
information about the results of clinical trials for
pharmaceuticals; testing, inspection or research on
pharmaceuticals, chemicals, cosmetics or foods and providing
information relating thereto; providing research information
and results in the fields of technology, science and
medicine from an online searchable database; providing
information about environmental conservation; testing and
inspection services relating to environmental conservation;
providing information about testing or research relating to
environmental conservation; research on building
construction or city planning; testing or research on
prevention of pollution; testing or research on electricity;
testing or research on civil engineering; testing,
inspection or research on agriculture, livestock breeding or
fisheries; testing or research on machines, apparatus and
instruments; rental of measuring apparatus; rental of
computers; providing computer programs on data networks;
software as a service [SaaS]; electronic storage of medical
records; electronic storage of records of personal health
information data of individuals such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; electronic data storage; rental of laboratory
apparatus and instruments. Beauty salons; barbershops; providing bath houses; massage
and therapeutic Shiatsu massage; chiropractic; moxibustion;
treatment for dislocated joints, sprain, bone fractures
[judo-seifuku]; bodywork therapy; acupuncture; provision of
medical and pharmaceutical information via the Internet;
provision of medical information relating to benefits, side
effects, interactions of pharmaceuticals and medications;
provision of medical information about pharmaceutical
products; medical, medicinal and pharmaceutical consultancy;
advisory services relating to pharmaceutical products;
provision of information on pharmaceuticals and medical
services through computer databases; medical testing for the
collection of medical information, analysis and provision of
medical information for diagnostic or treatment purposes;
medical testing; medical consultancy and diagnosis via the
Internet; online medical counseling services; remote
monitoring of patient health status for medical conditions;
remote monitoring of medical data for medical diagnosis and
treatment; analysis and provision of clinical data of
patients for diagnostic or treatment purpose; providing
medical information; physical examination; providing
information about pharmaceuticals, medical services or
health; consultancy services relating to medical services,
pharmaceuticals, health or dispensing of medications;
consultancy, advisory and provision of information relating
to dieting, nutritional intake or health care; consultancy,
advisory and provision of information relating to health
care; managed health care services; provision of records of
personal health information data such as weight, body fat,
body temperature, number of steps, sleeping hours and blood
pressure; nutritional consultancy and advisory for
preventing and decreasing obesity; provision of information
about nutritional consultancy and advisory for preventing
and decreasing obesity; dietary and nutritional guidance;
animal breeding; veterinary services; beautification for
animals; nursing care; rental of medical apparatus and
instruments.
48.
AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS
A suppression of postsurgical recurrence and/or metastasis of cancer by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery is disclosed. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, containing a beta-blocker and being administered during a perioperative period of cancer surgery.
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
EISAI R&D MANAGEMENT CO., LTD. (Japon)
ONO PHARMACEUTICAL CO., LTD. (Japon)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japon)
Inventeur(s)
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Takado, Yuhei
Matsuoka, Kiwamu
Mizuma, Hiroshi
Yamamoto, Takeshi
Wakabayashi, Takeshi
Ohfusa, Toshiyuki
Abrégé
Provided is a compound that has high binding selectivity to α-synuclein aggregates. The present invention relates to a compound represented by formula (I), (II) or (III), a pharmaceutically acceptable salt thereof, or a solvate of the compound or pharmaceutically acceptable salt.
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
51.
Compound having KDM5 inhibitory activity and pharmaceutical use thereof
Disclosed are compounds of following formula (I):
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
52.
IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST
A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer includes administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
53.
CANCER TREATMENT AGENT INCLUDING MALT1 INHIBITING DRUG AS ACTIVE INGREDIENT
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate, or a solvate thereof, demonstrates a strong antitumor effect, and thus is useful in treating blood cancer.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
55.
Bicyclic compound and use thereof for medical purposes
Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61K 31/558 - Eicosanoïdes, p. ex. leucotriènes ayant des hétérocycles contenant l'oxygène comme seul hétéro-atome du cycle, p. ex. thromboxanes
C07D 313/06 - Cycles à sept chaînons condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
56.
AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION
New uses of an FF-MAS metabolism inhibitor for protecting and/or regenerating a neuromuscular junction or for treating and/or preventing a disorder of a neuromuscular junction are disclosed. In one aspect, a method for protecting and/or regenerating a neuromuscular junction or a method for treating and/or preventing a disorder of a neuromuscular junction, the method including administering an effective amount of an FF-MAS metabolism inhibitor to a mammal is disclosed. In one aspect, an FF-MAS metabolism inhibitor for use in protecting and/or regenerating a neuromuscular junction or for use in treating and/or preventing a disorder of a neuromuscular junction is disclosed. In one aspect, uses of an FF-MAS metabolism inhibitor for manufacturing an agent for protecting and/or regenerating a neuromuscular junction or for manufacturing an agent for treating and/or preventing a disorder of a neuromuscular junction are disclosed.
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61P 21/04 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire de la myasthénie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention provides a tablet comprising opicapone or a pharmaceutically acceptable salt thereof, having reduced tableting faults during manufacture. It further relates to a tablet comprising opicapone or a pharmaceutically acceptable salt thereof, wherein the tablet comprises particles of opicapone or pharmaceutically acceptable salt thereof having the following particle size, and a manufacturing method thereof:(i) a maximum length D50 value of 45 µm or less, and/or (ii) a maximum length D90 value of 110 µm or less
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
Provided is a compound having a GCL inhibitory activity. A compound represented by general formula (I) (all symbols in the formula are as defined in the description) or a salt thereof has GCL inhibitory activity, and therefore is useful for inhibiting progression, inhibiting reoccurrence, and/or treatment of GCL-related diseases such as cancer.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
[in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed.
The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient.
As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1)
[in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed.
Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
C07H 13/12 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques par des acides comportant le groupe —X—C (=X)—X—, ou leurs halogénures, dans lesquels chaque X signifie de l'azote, de l'oxygène, du soufre, du sélénium ou du tellure, p. ex. acide carbonique, acide carbamique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations; pharmaceutical substances;
anti-cancer preparations; chemical preparations for sanitary
purposes; chemical preparations for medicinal purposes;
diagnostic preparations for medical purposes; medicines for
veterinary purposes; medicated toiletry preparations;
sanitary preparations for medical purposes; fungicides;
sterilizing preparations; disinfectants for hygiene
purposes; pharmaceutical preparations for the treatment and
prevention of cardiovascular disorders, genitourinary
disorders, gynecological diseases and obstetric diseases,
cancer and its metastasis, eye disorders, neurologic
disorders, psychiatric disorders, endocrine and metabolic
disorders, allergic disorders, gastrointestinal disorders,
immune diseases and autoimmune diseases, respiratory
diseases, musculoskeletal and connective tissue disorders,
infectious diseases, dermatologic disorders, hematological
disorders, inflammatory diseases, ear, nose, dental and
throat disorders, hepatic and biliary disorders, Alzheimer's
disease, and diabetes and its complications; pharmaceutical
preparations for cancer supportive care; anesthetic,
sedative and analgesic drugs; vaccines; reagent paper for
medical purposes; vitamin preparations; pastilles for
pharmaceutical purposes; mint for pharmaceutical purposes;
medicated candies; chewing gum for medical purposes;
lecithin for medical purposes; greases for medical purposes;
cod liver oil; capsules for medicines; oiled paper for
medical purposes; adhesive tapes for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; gauze for dressings; empty
capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary napkins; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings; liquid
bandages; breast-nursing pads; cotton swabs for medical use;
dental materials; diapers; diaper covers; fly catching
paper; mothproofing paper; lacteal flour for babies; glucose
dietary supplements; lecithin dietary supplements;
nutritional supplements; dietary supplements mainly
consisting of seafood extracts in the form of powders,
pills, capsules, granules, jellies or liquids; dietary
supplements for humans; dietary fibre; lyophilized food
adapted for medical purposes; lyophilized meat adapted for
medical purposes; dietetic beverages adapted for medical
purposes; dietetic foods adapted for medical purposes;
beverages for babies; food for babies; nutritional
supplements for animals; dietary supplements for animals;
semen for artificial insemination. Beauty salon services; barber shop services; providing bath
houses; massage and therapeutic shiatsu massage;
chiropractic; moxibustion; treatment for dislocated joints,
sprain, bone fractures [judo-seifuku]; bodywork therapy;
acupuncture; provision of medical and pharmaceutical
information via the Internet; provision of medical
information relating to benefits, side effects, interactions
of pharmaceuticals and medications; provision of medical
information about pharmaceutical products; medical,
medicinal and pharmaceutical consultancy; advisory services
relating to pharmaceutical products; provision of
information on pharmaceuticals and medical services through
computer databases; medical testing for the collection of
medical information, analysis and provision of medical
information for diagnostic or treatment purposes; medical
consultancy and diagnosis via the Internet; online medical
counseling services; remote monitoring of patient health
status for medical conditions; analysis and provision of
clinical data of patients for diagnostic or treatment
purposes; provision of medical information; physical
examination; providing information about pharmaceuticals,
medical services or health; consultancy services relating to
medical services, pharmaceuticals, health or dispensing of
medications; consultancy, advisory and provision of
information relating to dieting, nutritional intake or
health care; consultancy, advisory and provision of
information relating to health care; managed health care
services; provision of records of personal health
information data such as weight, body fat, body temperature,
number of steps, sleeping hours and blood pressure;
nutritional consultancy and advisory for preventing and
decreasing obesity; provision of information about
nutritional consultancy and advisory for preventing and
decreasing obesity; dietary and nutritional guidance; animal
breeding; veterinary services; beautification for animals;
nursing care; rental of medical apparatus and instruments.
A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
62.
METHOD FOR REMOVING COLOR FROM DRUG SUBSTANCE OF PROTEIN PREPARATION
A method for removing coloration from a drug substance solution of protein preparation, in particular, antibody preparation, a method for preparing drug substance solution of protein preparations including it, as a part thereof, and highly concentrated, colorless drug substance solutions thereof are disclosed. The method removes terminal glycation products causing the coloration in the drug substance solution of protein preparation, in particular, antibody preparation, by anion-exchange chromatography, making it possible to provide colorless drug substance solutions.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
B01D 15/16 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives au conditionnement du fluide vecteur
B01D 15/42 - Adsorption sélective, p. ex. chromatographie caractérisée par le mode de développement, p. ex. par déplacement ou par élution
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines Personal digital assistants; downloadable and recorded application software for use in medical diagnostic, testing, analysis or provision of medical information; downloadable and recorded computer programs for use in medical diagnostic, testing, analysis or provision of medical information; computers; downloadable and recorded computer programs and software for use in medical diagnostic, testing, analysis or provision of medical information; computer hardware; computer systems; computer terminals; computer peripheral devices; downloadable and recorded game programs for home video game machines; downloadable music files; downloadable image files containing medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable video files featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable digital books in the field of medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable electronic newspapers; downloadable electronic publications in the nature of books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare recorded on disc; audio and video recordings featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare Designing of machines, apparatus, instruments including their parts or systems composed of such machines, apparatus and instruments; industrial design services; computer software design, computer programming, or maintenance of computer software relating to medical data; design and development of computer software for use with medical technology; development and creation of computer programmes for data processing; rental of computers and software for data processing; computer software design, computer programming, or maintenance of computer software; database design and development; technological advice being technological consulting relating to computers, automobiles and industrial machines; pharmaceutical research; providing information relating to pharmaceutical research; providing information relating to testing or research on pharmaceuticals via the Internet; research and development of pharmaceuticals and biopharmaceuticals for treatment and diagnosis of human disease; research and survey of pharmaceuticals for gene analysis; providing information relating to research and development of pharmaceuticals in response to customers' request via the Internet; providing information about medical and scientific research in the field of pharmaceuticals; conducting clinical trials for others; clinical trials for pharmaceuticals for others; conducting clinical trials for pharmaceutical products at medical institutions for others; providing information about the results of clinical trials for pharmaceuticals; testing, inspection and research on pharmaceuticals, chemicals, cosmetics or foods and providing information relating thereto; providing medical and scientific research information and results in the fields of technology, science and medicine from an online searchable database; providing information about scientific research in the field of environmental conservation; testing and inspection services relating to scientific research in the field of environmental conservation; providing information about testing or scientific research relating to environmental conservation; rental of measuring apparatus; rental of computers; providing online non-downloadable computer programs on data networks for use in medical diagnostic, testing, analysis or provision of medical information; software as a service [SaaS] featuring software for use in medical diagnostic, testing, analysis or provision of medical information; electronic storage of medical records; electronic storage of records of personal health information data of individuals such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; electronic data storage; rental of laboratory apparatus and instruments Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nursing care; rental of medical apparatus and instruments
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines; dietary supplements mainly consisting of seafood extracts in the form of powders, pills, capsules, granules, jellies or liquids; beverages for babies, namely, infant formula; food for babies Personal digital assistants; downloadable and recorded application software for use in medical diagnostic, testing, analysis or provision of medical information; downloadable and recorded computer programs for use in medical diagnostic, testing, analysis or provision of medical information; computers; downloadable and recorded computer programs and software for use in medical diagnostic, testing, analysis or provision of medical information; computer hardware; computer systems; computer terminals; computer peripheral devices; downloadable and recorded game programs for home video game machines; downloadable music files; downloadable image files containing medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable video files featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable digital books in the field of medical and scientific research in the field of pharmaceuticals, medical care and healthcare; downloadable electronic newspapers; downloadable electronic publications in the nature of books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare; books featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare recorded on disc; audio and video recordings featuring medical and scientific research in the field of pharmaceuticals, medical care and healthcare Designing of machines, apparatus, instruments including their parts or systems composed of such machines, apparatus and instruments; industrial design services; computer software design, computer programming, or maintenance of computer software relating to medical data; design and development of computer software for use with medical technology; development and creation of computer programmes for data processing; rental of computers and software for data processing; computer software design, computer programming, or maintenance of computer software; database design and development; technological advice being technological consulting relating to computers, automobiles and industrial machines; pharmaceutical research; providing information relating to pharmaceutical research; providing information relating to testing or research on pharmaceuticals via the Internet; research and development of pharmaceuticals and biopharmaceuticals for treatment and diagnosis of human disease; research and survey of pharmaceuticals for gene analysis; providing information relating to research and development of pharmaceuticals in response to customers' request via the Internet; providing information about medical and scientific research in the field of pharmaceuticals; conducting clinical trials for others; clinical trials for pharmaceuticals for others; conducting clinical trials for pharmaceutical products at medical institutions for others; providing information about the results of clinical trials for pharmaceuticals; testing, inspection and research on pharmaceuticals, chemicals, cosmetics or foods and providing information relating thereto; providing medical and scientific research information and results in the fields of technology, science and medicine from an online searchable database; providing information about scientific research in the field of environmental conservation; testing and inspection services relating to scientific research in the field of environmental conservation; providing information about testing or scientific research relating to environmental conservation; rental of measuring apparatus; rental of computers; providing online non-downloadable computer programs on data networks for use in medical diagnostic, testing, analysis or provision of medical information; software as a service [SaaS] featuring software for use in medical diagnostic, testing, analysis or provision of medical information; electronic storage of medical records; electronic storage of records of personal health information data of individuals such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; electronic data storage; rental of laboratory apparatus and instruments Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to dieting, nutritional intake or health care; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nutritional consultancy and advisory for preventing and decreasing obesity; provision of information about nutritional consultancy and advisory for preventing and decreasing obesity; dietary and nutritional guidance; nursing care; rental of medical apparatus and instruments
66.
Compound having KDM5 inhibitory activity and pharmaceutical use thereof
Disclosed are compounds of following formula (I):
in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines
The present disclosure provides the methods for making 4-[4-cyano-2-({[(2'R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1'-cyclopropan]-2'-yl]carbonyl}amino)phenyl]butanoic acid. The present disclosure also generally relates to intermediates useful in the said methods.
C07D 311/96 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, condensés avec d'autres cycles condensés en spiro avec des carbocycles ou avec des systèmes carbocycliques
The present invention addresses the problem of providing: a method for producing a fluorinated imidazole with a good yield; and a method for producing an imidazole compound having a high optical purity. As a result of diligent research, the inventors of the present invention found that a fluorinated imidazole could be obtained at a high yield by using a compound Y. In addition, the inventors of the present invention found that compound Y having a high optical purity could be obtained by subjecting a salt of compound Y and cinchonidine to a purification process by means of recrystallization. By using compound Y having high optical purity as a production intermediate, it is possible to provide a compound X having a high optical purity as a medicinal drug.
C07D 453/02 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation
C07D 453/04 - Composés hétérocycliques contenant des systèmes cycliques quinuclidine ou isoquinuclidine, p. ex. alcaloïdes de la quinine contenant des systèmes cycliques quinuclidine sans autre condensation comportant lié en position 2 un radical quinolyle-4, un radical quinolyle-4 substitué ou un radical alkylènedioxy quinolyle-4 lié par un seul atome de carbone, p. ex. quinine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for medicinal purposes for treating cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; diagnostic preparations for medical purposes; medicated toiletry preparations; sanitary preparations for medical purposes; fungicides; sterilizing preparations; disinfectants for hygiene purposes; pharmaceutical preparations for the treatment and prevention of cardiovascular disorders, genitourinary disorders, gynecological diseases and obstetric diseases, cancer and its metastasis, eye disorders, neurologic disorders, psychiatric disorders, endocrine and metabolic disorders, allergic disorders, gastrointestinal disorders, immune diseases and autoimmune diseases, respiratory diseases, musculoskeletal and connective tissue disorders, infectious diseases, dermatologic disorders, hematological disorder, inflammatory diseases, ear, nose, dental and throat disorders, hepatic and biliary disorders, Alzheimer's disease, and diabetes and its complications; pharmaceutical preparations for cancer supportive care; general and topical anesthetic, sedative and analgesic drugs; vaccines Provision of medical and medical pharmaceutical information via the Internet; provision of medical information relating to medical benefits, side effects, interactions of pharmaceuticals and medications; provision of medical information about pharmaceutical products; medical, medicinal and pharmaceutical consultancy; advisory services relating to pharmaceutical products; provision of information on pharmaceuticals and medical services through computer databases; medical testing for the collection of medical information, analysis and provision of medical information for diagnostic or treatment purposes; medical testing; medical consultancy and diagnosis via the Internet; online medical counseling services; remote monitoring of patient health status for medical conditions; remote monitoring of medical data for medical diagnosis and treatment; analysis and provision of clinical data of patients for medical diagnostic or treatment purposes; provision of medical information; physical examination; providing medical information about pharmaceuticals, medical services or health; consultancy services relating to medical services, pharmaceuticals, health or dispensing of medications; consultancy, advisory and provision of information relating to health care; managed health care services; provision of records of personal health information data such as weight, body fat, body temperature, number of steps, sleeping hours and blood pressure; nursing care; rental of medical apparatus and instruments
71.
COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST ACTIVITY AND PHARMACEUTICAL USE THEREOF
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):
wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.
C07D 207/22 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 207/34 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 209/70 - Systèmes cycliques contenant au moins trois cycles condensés en [b] ou en [c] contenant des carbocycles autres que des cycles à six chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
72.
CANCER TREATMENT METHOD BY COMBINED USE OF CD47 INHIBITORY SUBSTANCE, IMMUNE CHECKPOINT INHIBITORY SUBSTANCE, AND STANDARD THERAPY
The present invention addresses the problem of providing an effective cancer treatment method. Provided is a cancer treatment method in which are combined a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody, etc.), and a standard therapy (e.g., combination therapy of bevacizumab or cetuximab added to FOLFOX therapy for unresectable advanced or recurrent colorectal cancer, FOLFIRINOX therapy or a low-dose regimen thereof for pancreatic cancer with distal metastases). The treatment method according to the present invention is useful in cancer treatment.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
The present invention addresses the problem of providing an effective cancer treatment method. Provided is a cancer treatment method in which are combined a CD47 inhibitor, an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody, etc.), and a standard therapy (e.g., combination therapy of bevacizumab or cetuximab added to FOLFOX therapy for unresectable advanced or recurrent colorectal cancer, FOLFIRINOX therapy or a low-dose regimen thereof for pancreatic cancer with distal metastases). The treatment method according to the present invention is useful in cancer treatment.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A):
wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.
C07D 207/34 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07C 233/76 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons doubles
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
C07D 231/12 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
A61K 31/4174 - Arylalkylimidazoles, p. ex. oxymétazoline, naphazoline, miconazole
C07D 213/75 - Radicaux amino ou imino, acylés par un acide carboxylique, par l'acide carbonique ou par leurs analogues du soufre ou de l'azote, p. ex. des carbamates
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
C07C 323/29 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure provides a composition for improving cognitive function that comprises a fish roe lipid preparation. In one embodiment, provided is a composition for improving cognitive function that comprises a fish roe lipid preparation prepared so as to provide about 100 mg or more and less than 300 mg per day of DHA, wherein the cognitive function is the linguistic ability of a subject who takes regular exercise.
A61K 35/60 - Poissons, p. ex. hippocampesŒufs de poisson
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 31/685 - Diesters d'acide du phosphore avec deux composés hydroxyle, p. ex. phosphatidylinositols un des composés hydroxylés ayant des atomes d'azote, p. ex. phosphatidylsérine, lécithine
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound represented by general formula (I-A) (wherein all symbols are as defined in the description) or a pharmaceutically acceptable salt thereof has an ABHD6-inhibiting activity, and is therefore useful as a medicinal component having a potent ABHD6-inhibiting activity in the prevention and/or treatment of a diseases associated with ABHD6.
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound represented by general formula (I-A) (wherein all symbols are as defined in the description) or a pharmaceutically acceptable salt thereof has an ABHD6-inhibiting activity, and is therefore useful as a medicinal component having a potent ABHD6-inhibiting activity in the prevention and/or treatment of a diseases associated with ABHD6.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The present disclosure provides a composition for improving the quality of sleep, the composition containing a fish roe lipid preparation and a diacyl glyceryl ether.
A compound of formula (I-a):
A compound of formula (I-a):
A compound of formula (I-a):
wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
The compound disclosed is a KDM5 inhibitor represented by the general formula (Z):
wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
83.
SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR
An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
C07D 205/04 - Composés hétérocycliques comportant des cycles à quatre chaînons ne contenant qu'un atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
87.
COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST
44 receptor antagonist. The combination according to the present invention exhibits a strong antitumor effect and therefore is useful in cancer treatment.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I):
(wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
C07C 233/81 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes carboxyle
C07C 235/64 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés en position ortho à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07C 327/48 - Amides d'acides thiocarboxyliques ayant des atomes de carbone de groupes thiocarboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons
C07D 207/34 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/397 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à quatre chaînons, p. ex. azétidine
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5355 - Oxazines non condensées contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
90.
SALT, SOLVATE, AND CRYSTAL OF COMPOUND HAVING EP2 ANTAGONISTIC ACTIVITY
2222 receptor. Also provided are crystals of the compound I disclosed in the present invention, salts of the compound I, and solvates and crystal forms thereof serving as an active pharmaceutical ingredient.
C07C 235/56 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 15/08 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles gonadiques ou pour augmenter la fertilité, p. ex. inducteurs d'ovulation ou de spermatogénèse
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
The present invention provides: an antibody or an antigen-binding fragment thereof which binds to HER2, which is expressed in cancer cells, or a fragment of HER2; a HER2 targeting agent containing either of these; and a pharmaceutical composition containing the HER2 targeting agent.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
The present invention provides: an antibody or an antigen-binding fragment thereof which binds to HER2, which is expressed in cancer cells, or a fragment of HER2; a HER2 targeting agent containing either of these; and a pharmaceutical composition containing the HER2 targeting agent.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
95.
CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR
44 antagonist and an immune checkpoint inhibitor (e.g., an anti-PD-1 antibody). The treatment method according to the present invention is useful in cancer treatment.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
C07C 311/21 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à un atome de carbone d'un cycle aromatique à six chaînons
98.
A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR
The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
NON PROFIT ORGANIZATION JAPAN CLINICAL CANCER RESEARCH ORGANIZATION (Japon)
Inventeur(s)
Sunakawa, Yu
Matoba, Ryo
Abrégé
Provided is a method for predicting a response to an immune checkpoint inhibitor for a subject having cancer, the method comprising: a step (1) for determining one or more values or the presence or the absence of single nucleotide polymorphism (SNP), selected from the group consisting of: (i) abundance of microorganisms in feces or bowel content of the subject, (ii) genome pathway score in feces or bowel content of the subject, (iii) abundance of metabolic products in the blood, serum, or plasma of the subject, (iv) gene expression in the blood, serum or plasma of the subject, and (v) SNP of one or more genes selected from the group consisting of IL6R and NLRC5 of the subject; and a step (2) for predicting a response of the subject to an immune checkpoint inhibitor on the basis of the value obtained in the step (1).
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/12 - Gènes codant pour des protéines animales
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
100.
NOVEL COMPOUND, .ALPHA.-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF
NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY (Japon)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (Japon)
Inventeur(s)
Higuchi, Makoto
Ono, Maiko
Cho, Meiei
Yamamoto, Takeshi
Wakabayashi, Takeshi
Abrégé
An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
